Rhythm Pharmaceuticals, Inc. RYTM Single reportable segment — Interest Income (Expense), Nonoperating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s single reportable segment — interest income (expense), nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s single reportable segment — interest income (expense), nonoperating?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported single reportable segment — interest income (expense), nonoperating of $1.03M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s single reportable segment — interest income (expense), nonoperating changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s single reportable segment — interest income (expense), nonoperating decreased by 41.9% year-over-year, from $1.77M to $1.03M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s single reportable segment — interest income (expense), nonoperating?
- Over 3 years (2022 to 2025), Rhythm Pharmaceuticals, Inc.'s single reportable segment — interest income (expense), nonoperating has grown at a 89.1% compound annual growth rate (CAGR), from -$783K to -$5.29M.
- What does single reportable segment — interest income (expense), nonoperating mean?
- This metric reflects the net impact of interest earned on cash reserves versus interest paid on debt obligations. It serves as an indicator of the company's capital structure and its ability to generate returns on idle cash or manage its cost of borrowing. A positive balance indicates a net interest-earning position, while a negative balance indicates a net cost of debt.